| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/23/2006 | US20060039860 Delivering a biopolymer to a cell by forming a complex of a biologically active polymer and a cyclic amidinium-containing compound and associating the complex with the cell |
| 02/23/2006 | DE20023745U1 Method of modulating expression of an endogenous cellular gene in a cell to prevent gene activation or prevent repression of gene expression comprising contacting a target sequence with a zinc finger protein |
| 02/23/2006 | CA2577660A1 Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues |
| 02/23/2006 | CA2577036A1 Small interfering rna molecules against ribonucleotide reductase and uses thereof |
| 02/23/2006 | CA2576860A1 Methods for modulating lipoprotein and cholesterol levels in human |
| 02/23/2006 | CA2576233A1 Conjugate comprising an antagomir and a ligand |
| 02/22/2006 | EP1627919A1 An infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| 02/22/2006 | EP1627886A1 Polypeptide, cDNA encoding the same, and use of them |
| 02/22/2006 | EP1627061A2 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/22/2006 | EP1627051A2 Regulation of acheron expression |
| 02/22/2006 | EP1626755A2 Intravenous delivery of polynucleotides to cells in mammalian limb |
| 02/22/2006 | EP1626694A2 Vaccine accelerator factor (vaf) for improvement of vaccinations in poultry |
| 02/22/2006 | EP1626650A2 Methods and probes for identifying vulnerable plaque |
| 02/22/2006 | EP1434882A4 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes |
| 02/22/2006 | EP1370668B1 Leporipox-based vector vaccines |
| 02/22/2006 | EP1244805B1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 02/22/2006 | EP1212464B1 Diagnostics and therapeutics for osteoporosis |
| 02/22/2006 | EP1208086B1 Benzamide formulation with histone deacetylase inhibitor activity |
| 02/22/2006 | EP1062336B1 Modulators of the function of receptors of the tnf/ngf receptor family |
| 02/22/2006 | EP1040185B1 Neural precursor cells, method for the production and use thereof in neural defect therapy |
| 02/22/2006 | EP1000161B1 Anticoagulant fusion protein anchored to cell membrane |
| 02/22/2006 | EP0957929B1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/22/2006 | EP0787206B1 USE OF NEURITE LOCALIZED mRNAs FOR MEDICAL DIAGNOSIS AND THERAPEUTICS |
| 02/22/2006 | EP0656060B1 Androgen regulation with dna sequences of rat probasin gene |
| 02/22/2006 | EP0549615B1 Sugar modified oligonucleotides that detect and modulate gene expression |
| 02/22/2006 | CN1739030A Diagnosis and prevention of cancer cell invasion |
| 02/22/2006 | CN1738911A Solid surface for biomolecule delivery and high-throughput assay |
| 02/22/2006 | CN1738896A Composition and method for treating lupus nephritis |
| 02/22/2006 | CN1738829A New 2',5'-oligoadenylic acid analog |
| 02/22/2006 | CN1738648A Small interference RNA gene therapy |
| 02/22/2006 | CN1738624A Method of treatment of myocardial infarction |
| 02/22/2006 | CN1737144A Composite multiple epitope bivalent nucleic acid vaccine construction for foot-and-mouth disease |
| 02/22/2006 | CN1737037A Polyethylene imine nanometer gel and its uses |
| 02/22/2006 | CN1736490A Tubercle bacillus chimeric gene vaccine and preparation process thereof |
| 02/22/2006 | CN1736489A Process for preparing nano-granule of albumin |
| 02/22/2006 | CN1736365A Method for preparing nanometer particles of galactose hydroxyapatite-polylysine |
| 02/22/2006 | CN1243099C Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent |
| 02/22/2006 | CN1243021C Interleukin-18 binding proteins, their preparation and use |
| 02/21/2006 | US7002027 Drug delivery enhancing agents with cholic acid and monosaccharide groups for treating cancer by gene therapy; tissue or organs having an epithelial membrane |
| 02/21/2006 | US7002003 oligonucleotide with optimal nucleotide binding sites for transcription factor; signal trandsducers and activators of transcription (STAT); treating cancer |
| 02/21/2006 | US7001998 Nucleic acids encoding a chimeric glycosyltransferase |
| 02/21/2006 | US7001997 A metalloprotease having a proteolytic activity; treating various diseases such as diabetic nephropathy, glomerulonephritis, fibrosis, cirrhosis, osteopetrosis and herniated disk; drug screening kits |
| 02/21/2006 | US7001995 Synthetic human papillomavirus genes |
| 02/21/2006 | US7001891 Biodegradable polycation composition for delivery of an anionic macromolecule |
| 02/21/2006 | US7001890 Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
| 02/21/2006 | US7001881 joint-lubricating glycoproteins; polypeptide and O-linked oligosaccharide moiety [B(1-3)Gal-GalNAc]; antiarthritic agent maintains viscosity of synovial fluid; osteoarthritis |
| 02/21/2006 | US7001769 modulating cellular senescence in vitro by introducing a polynucleotide (gDNA or cDNA) encoding an amphiphysin-1 protein; genetic engineering; genetic disorders, premature aging |
| 02/21/2006 | US7001765 immunotherapy; expression vector with foreign DNA coding for an immunostimulant protein; genetic vaccines with tumor antigens; anticarcinogenic, antitumor agents |
| 02/21/2006 | US7001764 Compositions comprising tissue specific adenoviral vectors |
| 02/21/2006 | US7001760 Hepatitis B virus vectors for gene therapy |
| 02/21/2006 | US7001614 Liposome complexes for increased systemic delivery |
| 02/21/2006 | US7001597 Methods for altering fertility |
| 02/21/2006 | US7001596 vector comprises tumor specific promoter, for killing neoplastic cells |
| 02/21/2006 | US7001589 comprises liquid core (containing hydrocarbon) and water soluble polymethylacrylamides as skins/envelopes; microencapsulation; kits |
| 02/21/2006 | CA2091181C Cloning of chicken anaemia dna |
| 02/16/2006 | WO2006017857A2 Antibiotic resistance free dna vaccines |
| 02/16/2006 | WO2006017816A2 Product and process for inhibition of biofilm development |
| 02/16/2006 | WO2006017741A2 Radiation inducible iex-1 promoter |
| 02/16/2006 | WO2006017673A2 Taj in neuronal function |
| 02/16/2006 | WO2006017567A2 Customizing stem cell-derived cardiomyocytes for transplantation |
| 02/16/2006 | WO2006017566A2 Modulation of bio-electrical rhythms via a novel engineering approach |
| 02/16/2006 | WO2006017522A2 Use of antisense oligonucleotides to effect translation modulation |
| 02/16/2006 | WO2006017325A2 Aav vector compositions and methods for enhanced expression of immunoglobulins the same |
| 02/16/2006 | WO2006017318A2 Methods for treating cancer using agents that inhibit wnt16 signaling |
| 02/16/2006 | WO2006016657A1 Drug for treating or preventing hcv infection |
| 02/16/2006 | WO2006016097A2 Vector comprising polymer modified sirna liposomes |
| 02/16/2006 | WO2006015853A2 Use of pax4 in pancreatic cell proliferation |
| 02/16/2006 | WO2006001810A3 Improved inhibitor nucleic acids |
| 02/16/2006 | WO2005094420A3 Materials and methods for treatment of inflammatory and cell proliferation disorders |
| 02/16/2006 | WO2005048957A3 Novel insertion sites in pox vectors |
| 02/16/2006 | WO2005020916A3 Myoblast treatment of diseased or weakened organs |
| 02/16/2006 | WO2004071430A3 RNAi TARGETING OF VIRUSES |
| 02/16/2006 | WO2004047720A3 Methods of inhibiting angiogensis via modification of a lysyl oxidase |
| 02/16/2006 | WO2004018697A3 Protease resistant ti-growth hormone releasing hormone |
| 02/16/2006 | US20060037092 Universal stem cells |
| 02/16/2006 | US20060037090 include muscle mass and/or fat deposition lean meat, lean back fat, sow prolificacy and/or sow longevity; insulin-like growth factor 2 (IGF2); drug screening |
| 02/16/2006 | US20060037087 Recombinant vectors for treating E coli infections more specifically those that result in post weaning diarrhea or scours |
| 02/16/2006 | US20060036089 33 human secreted proteins |
| 02/16/2006 | US20060035869 Inhibitors of epoxide hydrolases for the treatment of hypertension |
| 02/16/2006 | US20060035859 Treating severe and acute viral infections |
| 02/16/2006 | US20060035858 Methods for modulating lipoprotein and cholesterol levels in humans |
| 02/16/2006 | US20060035857 Methods and compositions for the diagnosis and treatment of cancer |
| 02/16/2006 | US20060035856 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035855 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035854 Compositions and methods for coating medical devices |
| 02/16/2006 | US20060035853 Methods for tailoring the immune response to an antigen or immunogen |
| 02/16/2006 | US20060035852 Genetic products differentially expressed in tumors and the use thereof |
| 02/16/2006 | US20060035851 Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair |
| 02/16/2006 | US20060035850 Plant thymidine kinases and their use |
| 02/16/2006 | US20060035849 Methods and composition for modulating type I muscle formation using pgc-1 alpha |
| 02/16/2006 | US20060035836 Treatment of acute coronary syndrome with an exendin |
| 02/16/2006 | US20060035835 Novel protein, production and use thereof |
| 02/16/2006 | US20060035825 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 02/16/2006 | US20060035824 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation |
| 02/16/2006 | US20060035815 Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
| 02/16/2006 | US20060035810 Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto |
| 02/16/2006 | US20060035371 Hybrid adeno-retroviral vector for the transfection of cells |
| 02/16/2006 | US20060035326 Genes |
| 02/16/2006 | US20060035320 Immunoglobulin frameworks which demonstrate enhanced statbility in the intracellular envioronment and methods of identifying same |
| 02/16/2006 | US20060035303 JNK3 modulators and methods of use |